An interventional study of Pain reprocessing therapy (PRT) and Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) in Pain, Chronic and Back Pain, sponsored by Weill Medical College of Cornell University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by Weill Medical College of Cornell University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Chronic Pain by Weill Medical College of Cornell University — 5 open to participants now, 6 under way, none of them phase 3. Chronic Pain · Weill Medical College of Cornell University.
Among the 18 studies in Chronic Pain by Weill Medical College of Cornell University, this one is the 3rd largest by enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2023, is one of 13 with no phase, and was the 13th registered.
3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →5 of the 18 studies in Chronic Pain by Weill Medical College of Cornell University are open now, in 1 country. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 60+
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 18+
Weill Medical College of Cornell University · Sites in United States
Ages 21+
Weill Medical College of Cornell University · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 165 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 95 across the 15 interventional studies, 55 across the 3 observational. Of the 11 that completed or were terminated, 5 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
Weill Medical College of Cornell University is the lead sponsor of 893 studies on the registry; 165 are open to participants now.
Of its 124 completed or terminated interventional studies of FDA-regulated products, 95 (77%) have results posted.
4 of the studies in Chronic Pain by Weill Medical College of Cornell University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06671925Weill Medical College of Cornell UniversityA Community Health Worker-Led Program for Chronic Pain and Loneliness in Older Adults | 2027-05-31 |
| NCT07225049Weill Medical College of Cornell UniversityIntegrated PTSD and Chronic Pain Treatment | 2027-08 |
| NCT06800209Weill Medical College of Cornell UniversityPain Reprocessing Therapy in Post-Operative Knee Pain | 2027-09-30 |
| NCT06168604Weill Medical College of Cornell UniversityEvaluating the Efficacy of the Pain Identification and Communication Toolkit | 2027-10-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 18 studies in Chronic Pain by Weill Medical College of Cornell University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn which treatment works better for adults with chronic pain. This study is comparing three treatments: Pain Reprocessing Therapy (PRT), Cognitive Behavioral Therapy (CBT), and usual care (whatever a person is already doing to cope with their pain).
The study's main questions are:
This study will compare PRT, CBT, and usual care to see which is most helpful for lowering pain and helping with other problems that people with chronic pain can have.
Investigators recently developed a novel psychological treatment, pain reprocessing therapy (PRT). Using a combination of cognitive, exposure-based, and somatic psychotherapy techniques, PRT aims to promote patients' reconceptualization of pain as due to reversible, non-dangerous brain activity rather than peripheral pathology. Critically, PRT aims to reduce or eliminate pain, rather than increasing functioning.
In the first trial of PRT (N = 151), 66% of patients randomized to PRT were pain-free or nearly so at post-treatment, as compared to fewer than 20% of placebo and usual care controls. This trial was conducted in a primarily White, highly-educated population with face-to-face treatment, and how PRT effects would generalize to a more diverse population or to telehealth treatment is not known.
PRT was developed to better address pain intensity and pain-related outcomes compared to leading psychological treatments for pain such as cognitive behavioral therapy (CBT). This study aims to yield preliminary findings on the comparative efficacy of PRT vs. CBT vs. usual care. Developing scalable effective, non-pharmacological chronic pain treatments and testing their efficacy in racial/ethnic minorities is an urgent societal need. Accordingly, this study also tests a remotely-delivered PRT intervention in a diverse patient population.
Aim 1 of this study is to test the feasibility (recruitment \& retention) of conducting a randomized clinical trial comparing remotely-delivered PRT with an active comparator, CBT, and usual care and to assess the acceptability (helpfulness, satisfaction, \& impact) of PRT in a diverse, lower socioeconomic status (SES) patient population.
Aim 2 of this study is to test the comparative efficacy of PRT vs. CBT and PRT vs. usual care on pain intensity and other pain-related outcomes.
Additional resources became available during the study, allowing an increase in sample size from N = 75 to N = 150 to provide greater statistical power aim 2 (comparative efficacy). No interim analyses were conducted at any point, and investigators remained blind to study outcomes. The decision to expand the sample size was made after careful deliberation with Columbia and Cornell Roybal Center Advisory Committees.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Instability in living conditions or major interfering life events:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PRT has 5 components: 1) education about the origin of pain in the brain, its reversibility, and the pain-fear cycle; 2) reinforcing education using personal biography; 3) "somatic tracking" of pain through mindfulness and reappraisal of pain sensations as non-dangerous; 4) lowering the level of personal threat that may trigger pain sensation; and 5) inducing positive affect in periods of pain. Patients will attend 1 assessment and education telehealth session with a physician followed by 8, 50-minute, therapist-led sessions. Pacing will be flexible, ranging from 5-12 weeks, to increase accessibility. Treatment will be provided by experienced PRT clinicians. All PRT sessions will be remotely-delivered.
Behavioral: Pain reprocessing therapy (PRT)
CBT-CP, considered the leading psychological treatment for chronic pain, is a structured, time-limited intervention that aims to teach patients how to better manage chronic pain and improve their quality of life. Participants will receive 9, 50-minute sessions of CBT-CP over 5 - 12 weeks. The VA CBT-CP protocol contains an initial orientation involving education and familiarization with the CBT-CP approach to chronic pain. The protocol then includes sessions that focus on topics such as exercise, relaxation, pleasant activities, cognitive coping, and sleep. All CBT-CP sessions will be remotely-delivered.
Behavioral: Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)
Participants will be asked to continue whatever they are already doing to care for their back pain. Length of the usual care condition will be 5 weeks, the expected mean completion time of the PRT and CBT arms, and may be adjusted at mid-enrollment to match treatment arm length more closely.
Other: Usual care
A promising new psychotherapy for chronic pain
A psychotherapy for chronic pain that has 30+ years of research support.
Also known as: Cognitive Behavioral Therapy
Participants will be asked to continue to do whatever they are currently doing to manage their pain
Also known as: Treatment as usual
Pain Intensity
Last-week average pain intensity is assessed via the Brief Pain Inventory Short Form (BPI-SF). The BPI-SF assess pain severity and its impact on functioning. It consists of 9 total items including 4 pain items and 5 pain interference items. The 4 pain items measure pain in the last week on a numerical rating scale of 0 (no pain at all) to 10 (pain as bad as you can imagine). The reported score is the mean of the 4 pain items, yielding a total range of 0-10, with higher scores indicating greater pain severity.
Time frame: Primary time point is the day after post-treatment, 1.5 months on average
Session Attendance
Session attendance is a feasibility measure calculated as the percentage of people randomized to either PRT or CBT who attended at least 6 sessions.
Time frame: Assessed the day after post-treatment, an average of 1.5 months after randomization.
Pain Interference
Pain interference is assessed via the 5 pain interference items of the Brief Pain Inventory Short Form (BPI-SF). The BPI-SF assesses pain severity and its impact on functioning. It consists of 9 total items including 4 pain items and 5 pain interference items. The 5 pain interference items measure pain interference in the last week on a numerical rating scale of 0 (does not interfere) to 10 (completely interferes). The reported score is the mean of the 5 pain interference items, yielding a total range of 0-10, with higher scores indicating greater pain interference.
Time frame: Primary time point is the day after post-treatment, 1.5 months on average
Depression
Depression is assessed via the 8-item depression sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF), rated on a 5-point scale of 1 (never) to 5 (always). Raw scores (range 8-40) are converted to a T-score (mean 50, SD 10, U.S. general population norm); T-scores for this form range from 38.2 to 81.3, with higher scores indicating greater depressive symptoms.
Time frame: Primary time point is the day after post-treatment, 1.5 months on average
Positive Affect
Positive affect is assessed via the 5-item Positive Affect subscale (Attentive, Active, Alert, Inspired, Determined), asking respondents to indicate the extent to which each word describes how they felt in the past week. Each item is rated on a 5-point scale of 1 (very slightly or not at all) to 5 (extremely). Scores are summed across the 5 items, yielding a possible range of 5 to 25. A score of 5 indicates the lowest possible level of positive affect; a score of 25 indicates the highest possible level of positive affect.
Time frame: Primary time point is the day after post-treatment, 1.5 months on average
Anxiety
Anxiety is assessed via the 8-item anxiety sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF), rated on a 5-point scale of 1 (never) to 5 (always). Raw scores (range 8-40) are converted to a T-score (mean 50, SD 10, U.S. general population norm); T-scores for this form range from 37.1 to 83.1, with higher scores indicating greater anxiety.
Time frame: Primary time point is the day after post-treatment, 1.5 months on average
Anger
Anger is assessed via the 5-item anger sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF), rated on a 5-point scale of 1 (never) to 5 (always). Raw scores (range 5-25) are converted to a T-score (mean 50, SD 10, U.S. general population norm); T-scores for this form range from 32.9 to 82.9, with higher scores indicating greater anger.
Time frame: Primary time point is the day after post-treatment, 1.5 months on average
Sleep Disturbance
Sleep disturbance is assessed via the 8-item sleep disturbance sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF), rated on 5-point item-specific scales. Raw scores (range 8-40) are converted to a T-score (mean 50, SD 10, U.S. general population norm); T-scores for this form range from 30.5 to 77.5, with higher scores indicating greater sleep disturbance.
Time frame: Primary time point is the day after post-treatment, 1.5 months on average
Client Satisfaction
Client Satisfaction is assessed the Patients' Global Impression of Change (PGIC). The PGIC is a single-item self-report scale that measures a patient's belief about the efficacy of treatment. The single-item is rated on a 7-point scale of 0 (No change or condition has got worse) to 6 (a great deal better).
Time frame: Primary time point is the day after post-treatment, 1.5 months on average
Change in Pain Medication Use
Medication use is assessed by asking participants to provide the names, dosages, and frequencies of the medications that they are currently taking for pain management only. A blinded research assistant reviewed pre- and post-treatment responses and manually coded each participant as increasing, decreasing, or no change with regards to overall pain medication burden (number of pain medications, dose, frequency, and class: opioid \> prescription \> OTC). Cases with insufficient or unreliable data were excluded (e.g., a participant with multiple medications reported at baseline but none at post-treatment, suggestive of missing data).
Time frame: Primary time point is the day after post-treatment, 1.5 months on average
Participants were recruited via provider referral from primary care and pain medicine clinics affiliated with academic medical centers, and from community and religious centers serving diverse communities, supplemented by online recruitment (e.g., ResearchMatch, BuildClinical, Facebook) to support enrollment of a racially/ethnically diverse sample. Recruitment occurred at University of Colorado Anschutz Medical Campus (Aurora, CO).
| Milestone | Pain Reprocessing Therapy (PRT) | Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) | Usual Care |
|---|---|---|---|
| Started | 50 | 50 | 50 |
| Initiated treatment | 46 | 47 | 0 |
| Completed treatment | 39 | 40 | 0 |
| Withdrew from treatment, continued surveys | 3 | 4 | 0 |
| Observed at mid-treatment | 42 | 45 | 47 |
| Completed | 41 | 45 | 47 |
| Not completed | 9 | 5 | 3 |
| Withdrew: Withdrawal by subject | 3 | 2 | 3 |
| Withdrew: Lost to follow-up | 6 | 3 | 0 |
Last-week average pain intensity is assessed via the Brief Pain Inventory Short Form (BPI-SF). The BPI-SF assess pain severity and its impact on functioning. It consists of 9 total items including 4 pain items and 5 pain interference items. The 4 pain items measure pain in the last week on a numerical rating scale of 0 (no pain at all) to 10 (pain as bad as you can imagine). The reported score is the mean of the 4 pain items, yielding a total range of 0-10, with higher scores indicating greater pain severity.
| units on a scale | Pain Reprocessing Therapy (PRT) | Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) | Usual Care |
|---|---|---|---|
| Baseline | 5.52 ± 0.21 | 5.39 ± 0.21 | 5.34 ± 0.2 |
| Post-Treatment | 2.28 ± 0.25 | 4.33 ± 0.24 | 4.84 ± 0.24 |
Session attendance is a feasibility measure calculated as the percentage of people randomized to either PRT or CBT who attended at least 6 sessions.
| Participants | Pain Reprocessing Therapy (PRT) | Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) | Usual Care |
|---|---|---|---|
| Session Attendance | 39 | 41 | — |
Pain interference is assessed via the 5 pain interference items of the Brief Pain Inventory Short Form (BPI-SF). The BPI-SF assesses pain severity and its impact on functioning. It consists of 9 total items including 4 pain items and 5 pain interference items. The 5 pain interference items measure pain interference in the last week on a numerical rating scale of 0 (does not interfere) to 10 (completely interferes). The reported score is the mean of the 5 pain interference items, yielding a total range of 0-10, with higher scores indicating greater pain interference.
| units on a scale | Pain Reprocessing Therapy (PRT) | Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) | Usual Care |
|---|---|---|---|
| Baseline | 4.87 ± 0.28 | 5.26 ± 0.27 | 4.95 ± 0.26 |
| Post-Treatment | 1.47 ± 0.3 | 3.6 ± 0.3 | 4.25 ± 0.29 |
Depression is assessed via the 8-item depression sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF), rated on a 5-point scale of 1 (never) to 5 (always). Raw scores (range 8-40) are converted to a T-score (mean 50, SD 10, U.S. general population norm); T-scores for this form range from 38.2 to 81.3, with higher scores indicating greater depressive symptoms.
| T-score | Pain Reprocessing Therapy (PRT) | Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) | Usual Care |
|---|---|---|---|
| Baseline | 54.47 ± 1.52 | 53.37 ± 1.36 | 53.37 ± 1.31 |
| Post-Treatment | 48.56 ± 1.26 | 50.54 ± 1.25 | 51.8 ± 1.23 |
Positive affect is assessed via the 5-item Positive Affect subscale (Attentive, Active, Alert, Inspired, Determined), asking respondents to indicate the extent to which each word describes how they felt in the past week. Each item is rated on a 5-point scale of 1 (very slightly or not at all) to 5 (extremely). Scores are summed across the 5 items, yielding a possible range of 5 to 25. A score of 5 indicates the lowest possible level of positive affect; a score of 25 indicates the highest possible level of positive affect.
| units on a scale | Pain Reprocessing Therapy (PRT) | Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) | Usual Care |
|---|---|---|---|
| Baseline | 15.58 ± 0.56 | 15.7 ± 0.53 | 16.08 ± 0.59 |
| Post-Treatment | 18.82 ± 0.54 | 17.72 ± 0.53 | 16.13 ± 0.52 |
Anxiety is assessed via the 8-item anxiety sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF), rated on a 5-point scale of 1 (never) to 5 (always). Raw scores (range 8-40) are converted to a T-score (mean 50, SD 10, U.S. general population norm); T-scores for this form range from 37.1 to 83.1, with higher scores indicating greater anxiety.
| T-score | Pain Reprocessing Therapy (PRT) | Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) | Usual Care |
|---|---|---|---|
| Baseline | 56.27 ± 1.5 | 56.93 ± 1.54 | 54.27 ± 1.49 |
| Post-Treatment | 52.93 ± 1.44 | 53.23 ± 1.43 | 52.84 ± 1.41 |
Anger is assessed via the 5-item anger sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF), rated on a 5-point scale of 1 (never) to 5 (always). Raw scores (range 5-25) are converted to a T-score (mean 50, SD 10, U.S. general population norm); T-scores for this form range from 32.9 to 82.9, with higher scores indicating greater anger.
| T-score | Pain Reprocessing Therapy (PRT) | Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) | Usual Care |
|---|---|---|---|
| Baseline | 52.83 ± 1.58 | 53.2 ± 1.47 | 52.44 ± 1.49 |
| Post-Treatment | 46.87 ± 1.3 | 50.21 ± 1.27 | 50.21 ± 1.25 |
Sleep disturbance is assessed via the 8-item sleep disturbance sub-scale of the Patient Reported Outcome Measurement Information System Short Form (PROMIS-SF), rated on 5-point item-specific scales. Raw scores (range 8-40) are converted to a T-score (mean 50, SD 10, U.S. general population norm); T-scores for this form range from 30.5 to 77.5, with higher scores indicating greater sleep disturbance.
| T-score | Pain Reprocessing Therapy (PRT) | Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) | Usual Care |
|---|---|---|---|
| Baseline | 57.6 ± 1.17 | 57.37 ± 1.04 | 56.42 ± 1.35 |
| Post-Treatment | 50.94 ± 1.27 | 52.31 ± 1.26 | 54.85 ± 1.24 |
Client Satisfaction is assessed the Patients' Global Impression of Change (PGIC). The PGIC is a single-item self-report scale that measures a patient's belief about the efficacy of treatment. The single-item is rated on a 7-point scale of 0 (No change or condition has got worse) to 6 (a great deal better).
| units on a scale | Pain Reprocessing Therapy (PRT) | Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) | Usual Care |
|---|---|---|---|
| Client Satisfaction | 5.10 ± 1.02 | 3.69 ± 1.99 | 1.74 ± 1.76 |
Medication use is assessed by asking participants to provide the names, dosages, and frequencies of the medications that they are currently taking for pain management only. A blinded research assistant reviewed pre- and post-treatment responses and manually coded each participant as increasing, decreasing, or no change with regards to overall pain medication burden (number of pain medications, dose, frequency, and class: opioid \> prescription \> OTC). Cases with insufficient or unreliable data were excluded (e.g., a participant with multiple medications reported at baseline but none at post-treatment, suggestive of missing data).
| Participants | Pain Reprocessing Therapy (PRT) | Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) | Usual Care |
|---|---|---|---|
| Decrease | 15 | 7 | 8 |
| Increase | 0 | 1 | 5 |
| No Change | 21 | 23 | 28 |
Collected over Enrollment until end of 12-month follow-up. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pain Reprocessing Therapy (PRT) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) |
| Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) |
| Usual Care | 0/50 (0%) | 0/50 (0%) | 0/50 (0%) |
| Age, Continuous(years) | Pain Reprocessing Therapy (PRT) | Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) | Usual Care | Total |
|---|---|---|---|---|
| Mean | 48.9 ± 15.1 | 50.7 ± 14.9 | 49.5 ± 15.4 | 49.7 ± 15.0 |
| Sex: Female, Male(Participants) | Pain Reprocessing Therapy (PRT) | Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) | Usual Care | Total |
|---|---|---|---|---|
| Female | 29 | 32 | 31 | 92 |
| Male | 21 | 18 | 19 | 58 |
| Race (NIH/OMB)(Participants) | Pain Reprocessing Therapy (PRT) | Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) | Usual Care | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 2 | 0 | 4 |
| Asian | 5 | 1 | 2 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 7 | 11 | 11 | 29 |
| White | 31 | 33 | 36 | 100 |
| More than one race | 2 | 1 | 1 | 4 |
| Unknown or Not Reported | 3 | 2 | 0 | 5 |
| Ethnicity (NIH/OMB)(Participants) | Pain Reprocessing Therapy (PRT) | Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) | Usual Care | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 2 | 4 | 11 |
| Not Hispanic or Latino | 44 | 48 | 46 | 138 |
| Unknown or Not Reported | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Investigators will share de-identified project data publicly under Data Use Agreements that safeguard individual participant confidentiality and privacy. The study will produce the following types of data. All data will be available for sharing, except where noted, upon the date of the online publication of the results of the primary study aims: Patient-reported outcomes: All patient-reported outcomes will be de-identified and shared in raw form. Measures of treatment engagement: Deidentified values (e.g. number of treatment sessions attended) will be shared in raw form. Audio-video recordings of therapy sessions: These will be used in planned future research. Upon publication of a manuscript referencing these data, deidentified subject-level summary statistics (e.g., metrics of patient-provider vocal synchrony) will be shared.
Time frame: Complete, clean, de-identified copies of the data components described above, along with data dictionaries and metadata, will be publicly posted along with data use agreements by the online publication date of the primary aims in a peer-reviewed journal.
Access criteria: Data Use Agreements will ask users to not attempt to re-identify participants, either by merging in administrative, census, medical, or other data, or by using a software program that might re-identify participants. Investigators will consult as needed with the Cornell Research Data Management Service Group (RDMSG). As described in the Cornell Roybal Center overall data sharing plan, through the Cornell Roybal Center Investigator Development Program investigators will be able to access instruction and assistance to meet other requests for information that ensure research transparency and reproducibility: documentation about study aims; hypotheses/research questions; variable sources (e.g. outcome variables, covariates); measure/index construction; and publication information.
Ran from Apr 2023 to primary completion in Aug 2025, 28 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's 28 months is above that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
Completion moved once since we started tracking on Sep 25, 2026: Sep 2026 → Aug 2026, on Oct 27, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Weill Medical College of Cornell University →